Merck, 69452-3, HMS174 Competent Cells - Novagen

General description
Genotype: F⁻recA1 hsdR(rK₁₂⁻ mK₁₂⁺) (Rif R)

This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.
HMS174 strains provide the recA mutation in a K-12 background. Like BLR, these strains may stabilize certain target genes whose products may cause the loss of the DE3 prophage.
HMS174 strains provide high transformation efficiencies and the recA mutation in a K-12 background. Strain may stabilize certain target genes whose products may cause the loss of the DE3 prophage.
Other Notes
0.4 ml1 mlComponent

•2 × 0.2 ml5 × 0.2 mlHMS174 Competent Cells

•2 × 2 ml4 × 2 mlSOC Medium

•10 µl10 µlTest Plasmid

Legal Information
NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Multiple Toxicity Values, refer to MSDS (O)